

Recipharm boosts BFS capacity with strategic manufacturing investment

- *New BFS line adds significant sterile manufacturing capacity to support growing customer demand*
- *With 50 years of BFS expertise, Recipharm supports ophthalmic and vaccine programmes*
- *Integrated BFS capabilities span early feasibility, clinical supply and commercial manufacturing*

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line, expanding capacity to support customer programmes from development through commercial supply. The investment builds on 50 years of BFS expertise and further strengthens Recipharm's position in sterile drug product development and manufacturing.

The expanded capacity will support a broad range of ophthalmic product programmes, backed by dedicated local execution teams and a global network of experts.

Greg Behar, CEO of Recipharm, said: "Customers need sterile manufacturing partners that can combine technical expertise, operational scale and reliable delivery. This investment expands Recipharm's BFS capacity, strengthens our technical offering and positions Recipharm to meet growing customer demand with the speed, scale and quality required for today's complex product programmes."

Recipharm's BFS capabilities include pilot-scale manufacturing for feasibility studies and early-stage supply; clinical-scale manufacturing for small batches and stability studies; and proven high-volume commercial production. Together, these capabilities support customer programmes as they progress toward commercial supply.

Recipharm provides BFS capabilities across biologics and small molecules, for ophthalmic application as well as vaccines. For products with more specific handling requirements, Recipharm offers specialised handling environments for oxygen- and temperature-sensitive formulations, including nitrogen atmosphere filling and temperature-controlled environments.

BFS technology delivers practical manufacturing and supply benefits. Its fully automated aseptic processing helps reduce contamination risk, while plastic containers simplify the supply chain through fewer components, no breakage risk and easier transport. Compared with traditional glass filling processes, BFS can also support lower cost of goods and a reduced carbon footprint.

Ends)

For more information

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced



therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.

For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com

Media contact:

Guenaelle Holloway, Head of marketing and communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708